Question

Passage A
The traditional justification for intellectual property (IP) rights, such as patents and copyrights, rests on the fundamental necessity of incentivizing capital-intensive innovation. Developing a genuinely novel technology, funding a multi-year pharmaceutical trial, or producing a comprehensive cultural work requires substantial upfront investment and assumes enormous financial risk. Rational actors will only undertake such precarious endeavors if they can temporarily monopolize the resulting profits to recoup their expenditures. Critics of the patent system often decry these temporary monopolies as market inefficiencies that artificially inflate prices and limit consumer access. However, this shortsighted view systematically overlooks the dire alternative: in the absence of robust, legally enforceable IP protections, innovators would inevitably resort to trade secrets to protect their investments. A regime dominated by secrecy fundamentally fractures the foundation of cumulative scientific and cultural progress. When discoveries are kept hidden behind corporate walls rather than published in standardized patent registries, subsequent researchers are forced to continuously duplicate foundational efforts. Consequently, society is deprived of the shared public reservoir of knowledge upon which long-term advancement ultimately depends. Thus, while patents unquestionably grant exclusive commercial rights to their holders, their true, enduring societal value lies in their function as a mechanism for compulsory public disclosure.

Passage B
While classical economic justifications for strong intellectual property rights focus heavily on rewarding individual creators and incentivizing initial investments, empirical observation of modern, highly complex industries reveals a markedly different reality. In fields characterized by sequential and complementary innovation—such as software development, semiconductor engineering, and biotechnology—excessively robust patent regimes frequently stifle, rather than stimulate, the overall pace of technological progress. This paradoxical phenomenon is often termed the "tragedy of the anticommons" by legal scholars. When a single new consumer product or medical therapy requires synthesizing dozens or even hundreds of previously patented foundational technologies, the downstream innovator faces nearly insurmountable transaction costs. Negotiating individual licenses with numerous disparate rights-holders—any one of whom can effectively veto the entire project by withholding consent or demanding exorbitant royalties—makes commercializing new, synthesized technologies prohibitively expensive. Consequently, heavily patented fields often experience severe stagnation, as potential innovators predictably abandon promising projects rather than attempt to navigate a dense, uncoordinated "thicket" of overlapping legal claims. In response, collaborative frameworks, such as open-source software licensing and shared genetic databases, have emerged precisely as a corrective mechanism to this gridlock, convincingly demonstrating that shared access to foundational tools is often a far more potent catalyst for ongoing innovation than artificial exclusivity.

Based on Passage A, how would its author most likely respond to the assertion in Passage B that robust patent regimes frequently stifle technological progress in fields of sequential innovation?